Skip to main content
. Author manuscript; available in PMC: 2023 Nov 16.
Published in final edited form as: J Am Chem Soc. 2022 Nov 2;144(45):20815–20824. doi: 10.1021/jacs.2c08770

Figure 4.

Figure 4.

Fragment 3 inhibits biogenesis of miR-372 in human AGS gastric cancer cells. (A) Abundance of mature miR-372 upon treatment with 3, as measured by RT-qPCR (n = 6). (B) Abundance of pre-miR-372 upon treatment with 3, as measured by RT-qPCR (n = 6). (C) miRnome-wide profiling of AGS cells treated with 3 (1 μM, n = 3). Dotted lines represent a false discovery rate (FDR) of 1% and variance of S0 (0.1). (D) De-repression of miR-372’s downstream target LATS2 upon treatment with 3, as measured by RT-qPCR (n = 6). (E) Levels of LATS2 protein upon treatment with 3 (10 μM), as measured by Western blotting (n = 3). *P < 0.05, **P < 0.01, ***P < 0.001, and ****P < 0.0001 as determined by one-way ANOVA compared to untreated samples. Data are reported as the mean ± SEM for all panels.